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Abstract
Background. While cardiovascular events remain the pri-
mary form of mortality in haemodialysis (HD) patients,
few centres are aware of the impact of the hydration status
(HS).Theaimofthisstudywastoinvestigatehowthemag-
nitude of the prevailing overhydration influences long-term
survival.
Methods. We measured the hydration status in 269 preva-
lent HD patients (28% diabetics, dialysis vintage = 41.2 ±
70 months) in three European centres with a body compo-
sition monitor (BCM) that enables quantitative assessment
of hydration status and body composition. The survival of
these patients was ascertained after a follow-up period
of 3.5 years. The cut off threshold for the definition of
hyperhydration was set to 15% relative to the extracellu-
lar water (ECW), which represents an excess of ECW of
∼2.5 l. Cox-proportional hazard models were used to com-
pare survival according to the baseline hydration status for
a set of demographic data, comorbid conditions and other
predictors.
Results. The median hydration state (HS) before the HD
treatment ( HSpre) for all patients was 8.6 ± 8.9%. The
unadjusted gross annual mortality of all patients was 8.5%.
The hyperhydrated subgroup (n = 58) presented  HSpre =
19.9 ± 5.3% and a gross mortality of 14.7%. The Cox
adjusted hazard ratios (HRs) revealed that age (HRage =
1.05, 1/year; P < 0.001), systolic blood pressure (BPsys)
(HRBPsys = 0.986 1/mmHg; P = 0.014), diabetes (HRDia =
2.766; P < 0.001), peripheral vascular disease (PVD)
(HRPVD = 1.68; P = 0.045) and relative hydration sta-
tus ( HSpre)( H R  HSpre = 2.102 P = 0.003) were the only
significantpredictorsofmortalityinourpatientpopulation.
Conclusion. The results of our study indicate that the hy-
dration state is an important and independent predictor of
mortalityinchronicHDpatientssecondaryonlytothepres-
ence of diabetes. We believe that it is essential to measure
the hydration status objectively and quantitatively in order
toobtainamoreclearlydefinedassessmentoftheprognosis
of haemodialysis patients.
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Introduction
The achievement of a normal hydration state (HS) is one of
the major targets of haemodialysis (HD) therapy. The con-
cept of ‘dry weight’ is clinically undisputed and an integral
part of the routine dialysis practice [1,2]. The abnormal
hydration state has been related to arterial hypertension,
dialysis-associated hypotension and other symptoms and
signs including pulmonary and peripheral oedema, heart
failure, left ventricular hypertrophy and other adverse car-
diovascular sequelae [3–5]. To determine the hydration
state, clinical surrogate parameters are used such as in-
terdialytic weight gain, ultrafiltrationrate or blood pressure
[6,7]. In several observational studies, registry data and
uncontrolled single-centre studies, the association between
hydration state and outcome has been described [8–13].
However, clinical findings are not always conclusive and
oftencontradictoryasdemonstratedforinterdialyticweight
gain and hydration state [14,15].
Traditionally, concepts to define a normal hydration
state in anuric dialysis patients have aimed mainly for the
achievement of clinically tolerable dialysis sessions (e.g.
the absence of hypotensive episodes) [16] or a clinically
desirable interdialytic period (e.g. the absence of interdia-
lytic hypertension).
One major cause for the dichotomy of findings and para-
doxical observations is the lack of a reliable method for the
assessment of individual euvolaemia, for the detection of
small changes in fluid volumes and even more importantly
for the prediction of a target endpoint such as an individual
normal hydration state in kilograms. Only such a method
would avoid the reliance on subjective changes in hydra-
tion state and would allow a reliable quantification of a
deviation from euvolaemia. In the present study, we used
a bioimpedance spectroscopy method that defines objec-
tively the individual hydration state on the basis of an in-
dividual’s normal extracellular volume, taking into account
the individual’s body composition. The bioimpedance
spectroscopy method applied was validated by iso-
tope dilution methods [17], by accepted reference body
composition methods [18,19], by techniques that measure
relative changes in fluid volumes [20] and by extensive
clinical assessment of the hydration state [21–24] in more
than 1000 healthy subjects and patients. The relationship
between the change in hydration state caused by ultrafiltra-
tion and the withdrawn ultrafiltration volume (UFV) was
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0.015 ± 0.8 l [24]. The aim of this study was to investigate
and quantify a possible link between hydration state and
risk of death in chronic HD patients.
Methods
Patients, HD treatment
All patients that received HD treatment in the three study
centres in 2003 and fulfilled the inclusion criteria were in-
cluded in the study, in total 269 prevalent patients (dialysis
vintage = 41.2 ± 70 months). The patients with pacemak-
ers/implanted defibrillators or amputation of a major limb
were excluded. The patients were measured once with the
body composition monitor (BCM), and all other clinical
data were collected simultaneously. The physicians and the
nurses were blinded from the hydration status (HS) results.
The survival of patients until 1 January 2007 (3.5 years
follow-up) was documented. Death was counted as the out-
come event, whilst patients who had received a transplant
(n=29)orleftthecentre(n=10)werecensoredatthetime
of the event. Details of the patient population are presented
in Table 1. HD therapy was performed three times per week
for 4–5 h with a mean blood flow of 420 ml/min. A ma-
jority of patients were treated using 4008 series Fresenius
Medical Care dialysis systems. Dialysis membranes were
primarily polysulphone and high-flux membranes. Intradi-
alytic weight loss (IDWL) was calculated as the difference
between the pre- and post-weight normalized to the post-
weight of the patient. Ultrafiltration volume (UFV) was
expressed as the effective volume removal.
Assessment of body composition and hydration state
Body composition and hydration state were assessed with
a portable whole body bioimpedance spectroscopy device
(BCM—Fresenius Medical Care D GmbH). The BCM
measures the impedance spectroscopy at 50 frequencies.
Measurements were performed before the start of the HD
treatment with the patient sitting relaxed in the dialysis
chair. Electrodes were attached to one hand and one foot
on the same side of the body. All measurements were
performed by one trained nurse—no failure of measure-
ment especially due to possible electrical interference was
recorded. The fluid volumes extracellular (ECW), intracel-
lular (ICW) and total body water (TBW) were determined
usingtheapproachdescribedbyMoissl[17].Thehydration
status,leantissuemass(LTM)andfatmasswerecalculated
based on a physiologic tissue model described by Chamney
[25]. To facilitate the comparison between patients, the
hydration state was normalized to the ECW ( HS =
HS/ECW). The patient population was divided into a hy-
perhydrated and a normohydrated groups using a cutoff of
15% for the relative hydration status ( HS > 15%). The
definition of hyperhydration for  HS > 15% is based on
the work described by Wabel et al. [26]. The boundary of
 HS > 15% represents the highest quartile of the mea-
sured population. The normohydrated group also included
patients with mild overhydration (6,8% <  HS ≤ 15%),
and these patient groups were not separated for further
analysis. LTM and Fat were normalized to the body surface
area to obtain lean tissue index (LTI = LTM/height2) and
fat tissue index (FTI = Fat/height2). The values for LTI
and FTI were compared to an age- and gender-matched ref-
erence population (n = 1248) [27]. Values below the 10th
percentileofthereferencepopulationwereregardedasclin-
icallysignificant.IthasbeendemonstratedinstudiesinHD
patients that the reproducibility of the used BIS device [co-
efficient of variation (CVECW = 2.6%; CVTBW = 2.6%)] is
far superior to the reproducibility of clinical measurements
like the blood pressure (CVBPsyspre = 8.5%; CVBPsyspost =
15.7%) [28]. Therefore, only one BCM measurement was
performed, while the blood pressure was averaged for six
consecutive dialysis treatments as described by Agarwal
[29].
The hydration status at the end of the treatments (HSpost)
was calculated by subtracting the UFV from the hydration
status at the start of the treatment (HSpre).
Lab tests, antihypertensive medication and instrumental
tests
The last monthly lab data before the treatment involving
the BCM measurement were recorded with regard to serum
albumin, haematocrit, urea, serum creatinine and serum in-
organic phosphates. Additionally, the number of antihyper-
tensive medications (AHT) was recorded—diuretics and
drugs administered for cardioprotective reasons were in-
cluded in the analysis.
No chest x-rays are routinely performed in the centres
involved in the study. Therefore, no cardiothoracic ratio
was available for the patients.
Symptoms
The symptoms were assessed with an advanced clinical
score [5]. To simplify the analysis, the signs and symptoms
were grouped into three classes: those of dehydration (in-
terdialytic weakness and dizziness, thirst after HD), those
of overhydration (dyspnoea, oedema, raised jugular venous
pressure, cough caused by fluid overload) and those of vas-
cular intolerance (cramps, hypotension, vomiting). The last
sixtreatmentsbeforethetreatmentinvolvingtheBCMmea-
surementwereanalysedfortheoccurrenceoftherespective
symptoms. Additionally, the average appearance of intradi-
alytic adverse events per HD treatment was calculated.
Comorbidities
The comorbidities recorded included diabetes, cardiovas-
cular problems (cardiac insufficiency, atrial fibrillation,
ischaemic heart disease, coronary artery disease) and pe-
ripheral vascular disease (PVD).
Statistics/analysis
Mean values and frequencies of the parameters were com-
pared by ANOVA or chi square test, as appropriate. The
levelofsignificancewassettoP<0.05.Survivalfunctions
according to the baseline hydration status were described
using the Kaplan–Meier technique. The log-rank test was1576 V . Wizemann et al.
Table 1. Patient characteristics of all patients and the subgroup of all hyperhydrated and all normohydrated patients
Hyperhydrated Normohydrated All
Number of patients 58 211 269
2 Transplanted 27 Transplanted 29 Transplanted
2 Centre change 8 Centre change 10 Centre change
Age (years) 65 ± 14.8 66 ± 15.2 65 ± 15
Weight (kg) 66.6 ± 14.1 72.9 ± 13.7 71.3 ± 14
BMI (kg/m2) 23.9 ± 3.8a,b 25.8 ± 4.8a 25.6 ± 4.7b
Diabetics (y/n) 15% 32% 28%
Cardiovascular problems (y/n) 32% 35% 35%
Peripheral vascular disease (y/n) 18.9% 12% 13%
Intradialytic adverse events (1/treatment) 2.9% 7.3% 6.5%
Albumin (g/l) 40 ± 44 1 ± 3.2 40.8 ± 3.4
Haematocrit (%) 31.1 ± 4.9 33 ± 4.3 33 ± 4.5
Urea removal rate (%) 72.4 ± 9.8 73.6 ± 11.7 73.3 ± 11.4
Phosphate (mmol/l) 2.0 ± 5.7 1.9 ± 1.4 1.9 ± 3.0
Creatinine (mg/dl) 6.6 ± 2.3 6.6 ± 2.4 6.5 ± 2.4
Dialysis vintage (months) 57.3 ± 88.8a 37.6 ± 62a 41.2 ± 70
Intradialytic weight loss (%) 3.7 ± 1.1 3.09 ± 1.1 3.29 ± 1.2
Ultrafiltration volume (l) 2.28 ± 0.76 2.25 ± 0.86 2.26 ± 0.84
Equilibrated (kT/V) 1.3 ± 0.3 1.36 ± 0.3 1.34 ± 0.3
Preblood pressuresys/dia (mmHg) 142 ± 17/77 ± 11 135 ± 22/74 ± 12 136 ± 21/75 ± 12
Postblood pressuresys/dia (mmHg) 143 ± 17a,b 128 ± 19a 133 ± 20b
78 ± 97 4 ± 10 75 ± 10
Number of antihypertensive medication 1.5 ± 1.5 1 ± 1.2 1 ± 1.3
Extracellular water (l) 17.6 ± 3.3 16.1 ± 3.0 16.5 ± 3.2
Total body water (l) 34.5 ± 7.3 33.3 ± 7.1 33.5 ± 7.1
Hydration statuspre (l) 3.5 ± 1.2c 0.9 ± 1.1c 1.4 ± 1.6c
Hydration statuspost (l) 1.3 ± 1.5c −1.25 ± 1.4c −0.7 ± 1.8c
Relative hydration statuspre (%) 19.9 ± 5.3c 5.7 ± 6.4%c 8.6 ± 8.9%c
Relative hydration statuspost (%) 8.2 ± 8.2c −8.9 ± 11.4c −5.6 ± 13.5c
Lean tissue index (kg/m2) 12.6 ± 3.2 12.8 ± 3.0b 12.7 ± 3b
Fat tissue index (kg/m2)6 . 4 ± 3.5c 8.8 ± 4.2c 8.2 ± 4.2c
Relative fat (%) 29.3 ± 11.1a,b 33.8 ± 10.6a 32.5 ± 10.8b
Mortality in 3.5 years 41% 30% 32%
aSignificantly different between the group ‘hyperhydrated’ and group ‘normohydrated’.
bSignificantly different between the group ‘all’ and group ‘hyperhydrated’.
cSignificantly different between all groups.
used for univariable comparisons. Cox-proportional haz-
ard models were used to compare survival according to the
baseline hydration status adjusting for demographic data
(age, gender), comorbid conditions (diabetes, cardiovascu-
lar problems and PVD) and other predictors (anthropomet-
ricindexes asLTIandFTI,dialysisvintage,bloodpressure,
IDWL, lab data as albumin, haematocrit, intact PTH, pre-
dialysis phosphate, pre-dialysis creatinine and a dialysis
dose as expressed by equilibrated Kt/V). Both Kaplan–
Meier curves and Cox model used the same endpoint (time
ofdeath),andpatientswerecensoredwhentheyweretrans-
ferred to another dialysis unit, received a kidney graft or
were still on extra-corporeal treatment on the final obser-
vation date (1 July 2007). When Cox-proportional hazard
regression was applied, stepwise methods were used to ob-
tain the best multivariate model. Estimated relative risks
(hazardratios)andtheir90%confidenceintervalswerecal-
culatedwiththeuseoftheestimatedregressioncoefficients
and their standard errors. The contribution of covariates to
explain the dependent variable was assessed by means of
a two-tailed Wald test, with P < 0.05 considered signifi-
cant. The proportion hazard assumption was checked for
each model by inspection of the complementary log minus
log plots. All statistical analyses were performed using the
SPSS software, version 15 (SPSS Inc., Chicago, IL, USA).
The Cox-proportional hazard regression was applied for
the highest tertile ( HS > 12%) and the highest quartile
( HS > 15%) of the population. In the further analysis,
the quartile analysis ( HS > 15%) was preferred over the
tertile analysis because this analysis demonstrated a higher
independent risk factor.
Results
The patient characteristics and the differences between all
patients, the hyperhydrated and the normohydrated patients
are recorded in Table 1. The dialysis vintage was highest
in the hyperhydrated group (57.3 months). The hyperhy-
drated patients were found to have a lower body mass index
(BMIHyH = 23.9 kg/m2;B M I NHy = 25.8 kg/m2;B M I all =
25.6 kg/m2) and a lower relative fat mass (relFatHyH =
29.3%; relFatNHy = 33.8%; relFatall = 32.5 kg) than the
normohydrated group and all patients. The systolic blood
pressure after the treatment was significantly higher in the
hyperhydrated patient group (postBPsys_HyH = 143 mmHg;
postBPsys_NHy = 128 mmHg; postBPsys_all = 133 mmHg),
while there was no difference in the blood pressures be-
fore the treatment. The hydration status before and after the
treatment was significantly different between all groups.The mortality risk of overhydration in haemodialysis patients 1577
The hyperhydrated patients presented the highest hydration
status (HSpre_HyH = 3.5 l; HSpre_NHy = 0.9 l; HSpre_all =
1.4 l/HSpost_HyH = 1.3 l; HSpost_NHy =− 1.25 l; HSpost_all =
−0.7 l).
Fig. 1. Kaplan–Meier curve separating the patients for the relative hydra-
tion status ( HS >15%).
Fig. 2. Hazard ratio of the relative hydration status ( HS >15%) for the
unadjusted analysis and the Cox adjusted model (together with the upper
and lower limits for the 90% confidence interval).
Table 2. Cox adjusted hazard ratios
90% confidence
interval
Hazard ratio Lower Upper Significance
Age (/year) 1.047 1.029 1.066 <0.001
BPsys (/mmHg) 0.986 0.979 0.995 0.014
Diabetes (y/n) 2.766 1.879 4.073 <0.001
Peripheral vascular
disease (y/n)
1.683 1.097 2.582 0.045
 HSpre (>15%) 2.102 1.389 3.179 0.003
The cumulative survival factored for the relative hydra-
tion status ( HS) is shown in a Kaplan–Meier analysis in
Figure 1.
Figure 2 shows the unadjusted and Cox adjusted hazard
ratios for the relative hydration status (unadjusted HRHS =
1.64, P = 0.033). The Cox adjusted hazard ratios (see
Table 2) reveal that age, systolic blood pressure, diabetes,
PVDs and relative hydration status are the only signifi-
cant predictors of mortality (HRage = 1.05, P < 0.001;
HRBPsys = 0.986, P = 0.014; HRDia = 2.766, P < 0.001;
HRPVD = 1.68, P = 0.045; HRHS = 2.102, P = 0.003).
Discussion
The results of our study indicate that the hydration state
is an important and independent predictor of mortality in
chronic HD patients secondary only to the presence of di-
abetes. Our patient mix is comparable to other published
European HD populations [30] although the mortality rate
of 8.5% is significantly lower than that reported in compa-
rable studies [30–32], but in the range of studies involving
patients under strict volume control [10]. These findings
are consistent with uncontrolled single-centre studies that
havedemonstratedanassociationbetweenexcellentcontrol
of hypertension and low mortality [10,13,33].
Our low mortality indicates that a healthier group of pa-
tients was investigated in the current study. This notion
is supported by a comparably high mean serum albumin
level as compared to DOPPS data of the HD populations
[34]. Serum albumin in dialysis patients is associated with
nutritional state [35], inflammation [36], MIA syndrome
[37], atherosclerosis [38,39] and concentration of free tox-
ins such as p-cresol [40]. The low overall mortality rate and
normal serum albumin concentrations in our study popula-
tion, which was treated with ultrapure dialysate, high-flux
membranes, high urea removal rates and low ultrafiltration
rates, may also account for the failure of albumin (<40 g/l)
as a predictor of outcome both in the unadjusted and ad-
justed Cox model. The only selection bias that might have
been introduced could have resulted from the exclusion
of patients with pacemakers and defibrillators from BCM
measurements.Thoughsmall,thisgroupofpatientsisprob-
ably at high risk.
Interestingly, the dialysis vintage was significantly
higher in the hyperhydrated group. To be sure that this
was not the reason for the increased survival in the hy-
perhydrated group, we set up an additional Cox model
forcing dialysis vintage into the model with the result that
the hazard ratio and the significance of the relative hydra-
tion status increased even further. Additionally, the dialysis
vintage showed a negative hazard ratio. With each addi-
tional month on dialysis, the risk was decreased by 0.3%.
Thus,thehigherdialysisvintageinthehyperhydratedgroup
was not the cause of the increased mortality risk.
Of major interest is that diabetic patients have a
significantly lower LTI and an increased FTI. In the
unadjusted analysis, LTI showed a clearly increased hazard
ratio, but as most patients in this category were diabetic
the impact of diabetes on mortality effectively takes into
account the influence of LTI. Thus, LTI was no longer1578 V . Wizemann et al.
significant in the Cox adjusted analysis. This finding is
also confirmed by a paper of Kakiya [41] who did not find
any predictive value of lean mass index after adjustment
with a multivariate model. Kakiya et al. used DEXA to
assess body composition, but as DEXA was not able to
differentiate between hyperhydration and muscle mass
they had no possibility to assess the hydration status [42].
In our survival analysis, the threshold for the relative
hydration status was set to  HS > 15% that is comparable
with a hyperhydration of ∼2.5 l [26]. This threshold might
appear to be low when compared to UFVs arising in many
dialysis centres. However, in our population we observed a
lowaveragehyperhydrationbeforethetreatment( HSall =
8.6 ± 8.9%; HSall = 1.4 ± 1.6 l). In many of our patients,
the IDWL was lower than that in other studies [11], which
is likely to be the consequence of a low dietary salt intake.
Thismayhavebeenonefactorcontributingtothelong-term
survival of the study population.
With regard to other possible study limitations, CRP
(which is known to be a factor influencing mortality) was
notmeasuredatthetimeoftheBCMmeasurementin2003.
Due to the inability to quantify the individual hydration
state,previousstudiesassessingtheoutcomehaveusedsur-
rogate parameters such as IDWL [43], inter-dialysis weight
gain and ultrafiltration rate [44]. However, those measure-
ments are also surrogates for patients’ compliance [45],
nutritional behaviour and even the ultrafiltration/dialysis
duration policy in the respective dialysis centre, which
may not always be linked to the baseline hydration state.
A patient can very well remain hyperhydrated despite the
low interdialytic weight gain. The causes of death could
not be separated into cardiovascular and noncardiovascu-
lar events since the majority of patients died at home. The
death certification is not reliable enough for specifying
correctly the cause of death. Therefore, no differentiation
between cardiovascular and non-cardiovascular events was
included.
In retrospective [43] and prospective cohort studies
[45,46], the association between such subjective measures
of hydration state and mortality is present only for sub-
groups of HD patients such as diabetics [43] or incident
patients [45] but can be absent or even reversed in young
and well-nourished patients [46]. The complex relationship
between fluctuations in hydration state in HD patients and
outcome clearly underlines the importance of an objective
target for normohydration. The advantage of our method is
that the individual body composition is taken into account
when calculating the overall hydration state. Thus, the con-
founding influence of the body composition assessed by
crude measures such as body mass index (BMI) is largely
eliminated.
In our study, we found a clear impact of the relative
hydrationstateonmortality,definedas>15%expansionof
ECW. A recent study has shown that 25% of patients suffer
from hyperhydration of >2.5 l [26], which is consistent
with the current study.
This study confirmed the association between hyperhy-
dration and higher mortality on the basis of a quantitative
method to estimate the hydration status. This association
does not necessarily imply a causal relationship: formal
clinical trials will be required to confirm the improvement
in survival once the dry body weight has been adjusted ac-
cording to the BCM’s indications. The reliability and sim-
plicityofusingthedevicewillfacilitatethis.Theresultswill
support its routine use in the follow-up of dialysis patients.
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